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Abstract
Background: Prevention, or slowing the progression, of diabetic nephropathy is one of the important goals in diabetes
care. Although the impact of depression is a concern in patients with diabetes, it is unknown whether there is an
association between adherence to hypoglycemic medication and the decline of renal function in comorbid patients
with diabetes and depression. We will conduct a cohort study aimed at examining (1) depression as a predictor of
renal function decline, and (2) how adherence to hypoglycemic medication relates to depression and renal function
decline in patients with type 2 diabetes.
Methods/Design: In this multicenter cohort study, 550 patients with type 2 diabetes aged 20 years and older will be
recruited at 20 outpatient clinics in general medicine and psychiatry. We will measure depression (Patient Health
Questionnaire), medication adherence (medication possession ratio, Morisky Medication Adherence Scale, and one-item
hypoglycemic medication adherence scale), and renal function (urinary albumin-creatinine ratio and estimated glomerular
filtration rate) at baseline and at the 12-month follow-up. The primary endpoint is decline of renal function at 12 months.
The secondary endpoints include clinical variables, quality of life, and the attitude of professionals toward depression. We
will perform multivariable linear regression analysis to evaluate the effects of medication adherence on the decline of
renal function in comorbid patients with type 2 diabetes and depression.
Discussion: To our knowledge, this will be the first study to examine how adherence to hypoglycemic medication
relates to the decline of renal function in comorbid patients with type 2 diabetes and depression. The results of the
study will have implications for practitioners of diabetes care, policy makers, and researchers for the prevention and
treatment of diabetic nephropathy.
Trial registration: UMIN000017513 (Registered on May 22, 2015)
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Background
Prevention, or slowing the progression, of diabetic ne-
phropathy is one of the important goals in diabetes care
[1, 2]. As the kidney disease progresses, end-stage renal
disease (ESRD) occurs and requires either dialysis or
transplantation, which places significant burden on the
patient and the society. Diabetes is one of the predictors
of a poor perceived quality of life in patients with ESRD
[3], and the prevalence of diabetes could impose an
increasing economic burden due to substantial costs for
patients with ESRD [4].
Depression is observed in approximately 20 % of pa-
tients with diabetes [5, 6]. Although adherence to
hypoglycemic medication is important for the prevention
and management of diabetic nephropathy [2], a meta-
analysis indicates that depression is associated with lower
adherence to hypoglycemic medication in patients with
diabetes [7]. Furthermore, depression also adversely
affects adherence to other key medications for hyperten-
sion and hyperlipidemia - the main risk factors of diabetic
nephropathy [8]. Considering the high prevalence of
depression and that depression is rather commonly
* Correspondence: ItoHiroto@ncnp.go.jp
1Department of Social Psychiatry, National Institute of Mental Health,
National Center of Neurology and Psychiatry, Tokyo, Japan
Full list of author information is available at the end of the article
© 2015 Ito et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ito et al. BMC Family Practice  (2015) 16:124 
DOI 10.1186/s12875-015-0339-1
undiagnosed in patients with diabetes [9], the impact of
depression on diabetic nephropathy is a growing concern.
The literature has reported the morbidity and mortal-
ity of kidney disease in patients with depression. A re-
cent meta-analysis showed that depression was observed
in 21.4 % of patients in chronic kidney disease (CKD)
stage 1–5 [10]. Comorbid patients with diabetes and de-
pression had higher risks of microalbuminuria [11] and
ESRD than those without depression [12]. Patients with
diabetic nephropathy who have had a depressive episode
were more likely undergo dialysis than those without a
depressive episode [13], and the mortality was 1.5-fold
higher in diabetes patients with depression than in those
without depression [14, 15].
In patients with type 2 diabetes, we aim to examine (1)
depression as a predictor of renal function decline, and
(2) how adherence to hypoglycemic medication relates
to depression and renal function decline.
Methods/design
Study design
This is a multicenter cohort study. We refer STROBE
reporting guidelines to this protocol (http://www.strobe-
statement.org/).
Ethical approval
The study protocol was approved by the institutional
review board (IRB) of the National Center of Neurology
and Psychiatry (NCNP) and participating clinics with
IRBs. The IRB of the NCNP approved the protocol for
those without IRB. This study is in accordance with the
Ethical Guidelines for Epidemiological Research (http://
www.niph.go.jp/wadai/ekigakurinri/guidelines.pdf ).
Study setting
This multicenter study will be conducted at 20 outpatient
clinics (NCNP, 5 from the Japan Diabetes Mellitus Effect-
ive Network System, and 14 from the Stress-Care In-
patient Care Network) in Japan. The Japan Diabetes
Mellitus Effective Network System is a network of primary
care physicians and specialists of diabetes collaborating to
prevent diabetes complications, whereas the Stress-Care
Inpatient Care Network consists of leading psychiatrists
aiming to improve the quality of psychiatric care for
patients with depression.
Participants
All patients who meet inclusion criteria during the study
period will be invited to participate in the study. Partici-
pants will be eligible for the study if they (1) are 20 years
and older, (2) outpatients with type 2 diabetes receiving
hypoglycemic medications, and (3) can complete a ques-
tionnaire in Japanese. Patients will be excluded if they
(1) have cognitive impairment, (2) are pregnant, and (3)
have severe disease of the adrenal glands, liver dysfunc-
tion, or severe renal impairment (serum creatinine ≥
2.0 mg/dL).
Eligible patients will be approached by physicians at
each site. After an explanation of the study, written in-
formed consent will be obtained from each patient. Pa-
tients will be able to access research staff members who
are not in charge of their treatment to withdraw from
the study at any time.
Study endpoints
The primary outcome is the decline of renal function in
four subtypes categorized according to depression and
adherence (depression/adherence: +/−, +/+, −/+, −/−) at
12 months. The secondary outcomes include clinical
variables, quality of life, and attitude of physicians to-
ward depression. We assess physician attitudes to de-
pression to confirm no effects of the attitudes on
primary outcome in a sensitivity analysis. Previous sys-
tematic review suggests necessity for cohort studies to
examine information on patients with multimorbidity
across all ages and socioeconomic groups [16]. Although
analyses of secondary outcomes will be underpowered,
we include the analyses in the protocol for confirmation
of the analysis of primary outcome and implication for
the future studies.
Data collection
Data will be collected at routine clinic visits by coordin-
ating staff at baseline and 12 months. The data include
patients’ demographic variables (e.g., age, gender, and
smoking status), body mass index, prescription, blood
pressure, laboratory data (e.g., glucose level, HbA1c,
total cholesterol, low- or high-density lipoprotein choles-
terol, triglycerides, serum creatinine, and urinary
albumin-creatinine ratio [ACR]), and diabetic complica-
tions. Table 1 shows the primary measures and timings
for measurement.
Renal function
Renal function will be assessed on the basis of ACR and
estimated glomerular filtration rate (eGFR) [17, 18], and
the decline of renal function is defined as ACR ≥ 30 mg/g
creatinine and eGFR < 60 mL⋅min−1⋅1.73 m−2.
Depression
Depression will be assessed by using the Patient Health
Questionnaire-9 (PHQ-9). The PHQ-9 is widely used in
patients with chronic diseases, including diabetes [8].
On the basis of a previous study [11], we operationally
define participants with PHQ-9 scores ≥ 10 as having de-
pressive symptoms. The reliability and validity of the
Japanese version of PHQ-9 have been established [19].
In this study, we define depression as having clinical
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diagnosis (DSM-5, American Psychiatric Association)
[20] or having both severe depressive symptoms and re-
ceiving antidepressant.
Medication adherence
Medication adherence will be assessed by using the
medication possession ratio (MPR). The MPR is defined
as the ratio of the number of days prescribed per
365 days based on medical records. The MPR is used as
an indicator for adherence improvement programs [21, 22].
In this study, we operationally define low adherence as <
80 % because a previous study reported that the mean ad-
herence ranged between 78 % and 82 % [23]. Medication
adherence will also be assessed by using the Japanese
version of the Morisky Medication Adherence Scores
(MMAS-8). MMAS-8 is an eight-item self-reporting meas-
ure of medication-taking behavior [24, 25]. The first seven
items have a dichotomous response (yes or no); the eighth
item has a five-point Likert scale response. The total score
of MMAS-8 ranges from 0 to 8. A higher score represents
a higher adherence to medication. In addition, a single-
question Oral Hypoglycemic Agent (OHA) adherence
scale will be used specifically to assess adherence to
hypoglycemic medication [23]. The question is, “On aver-
age, how would you rate your ability to take all your dia-
betes medications as your doctor prescribed?,” answered
with a five-point Likert scale (very poor, poor, fair, good,
very good, and excellent).
Quality of life
The quality of life of patients will be assessed by using
EuroQol. EuroQol is a generic measure of the respondents’
health-related quality of life and utility values [26, 27]. The
questionnaire consists of five items covering the areas of
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression (EQ-5D). Each item has three levels: no
problems, some problems, or extreme problems. The EQ-
5D scores are converted to a single index value (ranging
from 0 for the worst health state to 1 for the best health
state) [27]. A higher score represents a higher quality of
life. The reliability and validity of the Japanese version have
been established [28], and used in patients with diabetes in
Japan [29].
Attitude of physicians toward depression
Attitudes of physicians toward depression will be mea-
sured by using the Depression Attitude Questionnaire
(DAQ) [30]. This questionnaire consists of 20 items
based on three themes: the conceptual model of the re-
sponder, the respondents’ value judgments, and their
practical response. Answers are marked on a 100-mm
visual analogue scale ranging from “strongly disagree”
(0 mm) to “strongly agree” (100 mm). The DAQ has
been translated into Japanese, and its reliability and
validity have been verified [31]. Receiving completed
DAQ will be regarded as the physicians agree to partici-
pate in the questionnaire survey.
Sample-size calculations
We calculated sample size as 550 patients (165 for the
depression group and 385 for the non-depression group)
having (1) a 30 % prevalence of depression, (2) 10 % dif-
ference in microalbuminuria rate (18 % in the depression
group and 8 % in the non-depression group), and (3) an
88 % chance of detecting a true difference in microalbu-
minuria at the 5 % level of significance. Calculation was
based on the chi-square test with continuity correction
and we did not take into account of adherence since it
might be an intermediate variable. The prevalence of de-
pression in patients with diabetes was 20 % in previous
studies [5, 6, 10, 11]; however, we estimated 30 % owing
to the inclusion of patients from psychiatric clinics in
our study. The prevalence of microalbuminuria was esti-
mated by using the data of the Japanese Society of
Nephrology [18] and those from a previous study [11].
Data analysis
We will use multivariable linear regression analysis to
evaluate the effects of medication adherence of comor-
bid patients with type 2 diabetes and depression on the
decline of renal function. We will consider other poten-
tial confounding factors including smoking, hyperten-
sion, hyperlipidemia, and HbA1c. The risk of decline of
renal function will be estimated for four groups by ad-
herence (+/−) and depression (+/−) by odds ratio and
95 % confidence interval.
Table 1 Measures and timings for measurements
Scale Baseline 1 Year
Renal function urinary albumin-creatinine ratio (ACR)estimated glomerular
filtration rate (eGFR)
● ●
Depression Patient Health Questionnaire (9-item): PHQ-9 ● ●
Adherence Medication Possession Ratio (MPR)Morisky Medication Adherence
Scale (MMAS-8)Oral Hypoglycemic Agent (OHA) adherence
● ●
Quality of life EuroQol ● ●
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Discussion
To our knowledge, the present study will be the first
study to examine how adherence to hypoglycemic medi-
cation relates to the decline of renal function in comor-
bid patients with type 2 diabetes and depression. Given
the prevalence of diabetes and depression, the impact of
the comorbidity of these diseases is increasingly import-
ant. We will use all standardized measures. Renal func-
tion is assessed by urinary ACR and eGFR. As an
increase of ACR is observed earlier than a decrease of
eGFR in CKD, our study design aids in the better under-
standing of renal function decline from the early phase
in comorbid patients with type 2 diabetes and depres-
sion. Adherence is assessed by both objective (MPR) and
subjective (MMAS-8 and OHA) measures. MMAS-8
measures general adherence to medication, whereas
OHA specifically measures adherence to hypoglycemic
medication. A wide range of outcomes, including clinical
variables, quality of life, and attitude of professionals
toward depression, are also assessed.
This study design has several limitations. First, the par-
ticipants will be patients who regularly visit clinic, causing
a risk of bias. This might limit the generalizability of the
findings. Second, our study will not include all possible
confounding factors related to diabetes, depression,
hypoglycemic medication adherence, and decline of renal
function; nevertheless, we plan to control the major po-
tential confounding factors.
The results of the present study will have implications
to practitioners in diabetes care, policy makers, and re-
searchers for screening a group of patients at a high risk
for diabetic nephropathy (i.e., comorbid patients with
type 2 diabetes and depression plus poor adherence to
hypoglycemic medication) and for the development of
intervention strategies for the prevention and treatment
of diabetic nephropathy.
In conclusion, the results of this protocol study will indi-
cate the importance of depression in diabetic care through
exploring (1) depression as a predictor of renal function
decline, and (2) how adherence to hypoglycemic medica-
tion relates to depression and renal function decline. Our
research will provide insights to all clinicians who encoun-
ter comorbid patients with diabetes and depression in
dairy practice.
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